Clinical trials: COPD, completed
COPD
Vector Engineering Clinical
This study aimed to validate a novel automatic non-invasive ventilation (NIV) mode that continuously adjusts expiratory positive airway pressure (EPAP) to the lowest value that abolishes tidal expiratory flow limitation (EFL).
- Trial name
- NCT04725500
- Testing
- Auto-Titrating EPAP
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Pulmonary Disease, Chronic Obstructive
The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD
The objective of the study is to determine if a dual inhaled bronchodilator (Glycopyrrolate/Formoterol) is effective in increasing exercise time relative to placebo in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT03081156
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- William Stringer, md
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients
This study is a multicentre, open, randomised, parallel-group study with formoterol 9 μg one inhalation b.i.d, or standard COPD therapy.
- Trial name
- NCT01047553
- Testing
- Formoterol (OT)
- Where
- 27 sites in Japan
- Volunteers
- 251 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to see if treatment with AZD4818 for four weeks is tolerable, safe and effective in treating COPD and, if so, how it compares with placebo.
- Trial name
- TOP (NCT00629239)
- Testing
- AZD4818
- Where
- 12 sites in Denmark, Finland and 3 more
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.
This is a randomised, double-blind, double-dummy, multinational, multicentre, parallel group trial comparing tiotropium (18 mcg) inhalation capsule via HandiHaler and salmeterol (50 mcg) via MDI in patients with COPD.
- Trial name
- NCT00563381
- Testing
- Tiotropium bromide, Salmeterol
- Where
- 752 sites in Austria, Belgium and 23 more
- Volunteers
- 7,376 people
- Sponsor
- Boehringer Ingelheim
COPD
Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen
The main goal of this study is to evaluate the efficacy and safety of glycopyrronium bromide and indacaterol maleate and glycopyrronium bromide fixed dose combination (FDC) in patients with moderate COPD who switch from their…
- Trial name
- NCT01985334
- Testing
- Glycopyrronium, SABA, LABA
- Where
- 542 sites in Austria, Belgium and 21 more
- Volunteers
- 4,389 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study
The purpose of this study is to determine steady-state efficacy and dose response profile and to assess safety and pharmacokinetic profile of nebulized EP-101(SUN101) after 7-day dosing using an investigational high efficiency…
- Trial name
- NCT01426009
- Testing
- EP-101 via nebulizer (eFlow®) 25 ug, EP-101 via nebulizer (eFlow®) 50 ug, EP-101 via nebulizer (eFlow®) 100 ug
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 140 people
- Sponsor
- Sunovion Respiratory Development Inc.
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in…
- Trial name
- NCT01572792
- Testing
- Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate
- Where
- 208 sites in United States, Australia and 2 more
- Volunteers
- 921 people
- Sponsor
- AstraZeneca
COPD
A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD
Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg 2x a day will be given as an active comparator.
- Trial name
- GOLDEN 6 (NCT02038829)
- Testing
- SUN101 3 mcg, SUN-101 6.25 mcg, SUN-101 12.5 mcg
- Where
- 10 sites in United States
- Volunteers
- 96 people
- Sponsor
- Sunovion Respiratory Development Inc.
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This is a Phase IIb, randomized, double blind, chronic dosing (28 days), four period, five treatment, incomplete block, crossover design in subjects with moderate to severe COPD.
- Trial name
- PT009001 (NCT02196077)
- Testing
- BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, BFF MDI 80/9.6 μg
- Where
- 17 sites in United States
- Volunteers
- 180 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study was designed to provide pivotal confirmation of efficacy and safety data for 2 doses of indacaterol (150 and 300 µg once daily [od]) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00794157
- Testing
- Indacaterol 150 μg capsules, Indacaterol 300 μg capsules
- Where
- 60 sites in Hong Kong, India and 4 more
- Volunteers
- 347 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease, Acute Coronary Syndromes
Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes
Several studies and registries suggested that the concomitant presence of acute coronary syndromes (ACS) and chronic obstructive pulmonary disease (COPD) is significantly associated with poor prognosis.
- Trial name
- SCAP (NCT02324660)
- Testing
- screening test
- Where
- Italy
- Volunteers
- 137 people
- Sponsor
- University Hospital of Ferrara
Chronic Obstructive Pulmonary Disease
An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD
Patients who are hospitalized at select Carolinas Healthcare System (CHS) sites with Chronic Obstructive Pulmonary Disorder (COPD) acute exacerbation symptoms will be treated per the CHS COPD Clinical Pathway.
- Trial name
- NCT03207776
- Testing
- Usual Care, COPD Clinical Pathway
- Where
- 8 sites in United States
- Volunteers
- 4,832 people
- Sponsor
- Wake Forest University Health Sciences
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the effect of MEDI8968 on the rate of moderate or severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in adult subjects with symptomatic, moderate to very severe…
- Trial name
- SPRING (NCT01448850)
- Testing
- MEDI8968 600 mg IV, 300 mg SC
- Where
- 60 sites in United States, Bulgaria and 8 more
- Volunteers
- 464 people
- Sponsor
- MedImmune LLC
Pulmonary Disease, Chronic Obstructive
Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction
The main purpose of this study is to determine whether pharmacological treatment with N-acetylcysteine improves central and peripheral cardiorespiratory control and physical capacity in COPD patients with mild-to-moderate airflow…
- Trial name
- NCT02579772
- Testing
- N-acetylcysteine
- Volunteers
- 13 people
- Sponsor
- Queen's University
COPD, COPD Exacerbation Acute
ProAir Digihaler in COPD Disease Management: A Real World Study
A pilot study to explore the utilization of the TEVA ProAir Digihaler rescue medication use and inhalation parameters to identify disease deterioration to help in the management of COPD patients in clinical practice.
- Trial name
- NCT04821869
- Testing
- ProAir Digihaler, Digihaler
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Pulmonary Research Institute of Southeast Michigan
Chronic Obstructive Pulmonary Disease (COPD)
Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers
About 1 million individuals in the US have a prescription for supplemental oxygen (O2). Using O2 can prolong life and increase quality of life.
- Trial name
- PELICAN (NCT02098369)
- Testing
- Written education material (basic), Additional education material, PELICAN-Proactive
- Where
- 6 sites in United States
- Volunteers
- 444 people
- Sponsor
- University of Illinois Chicago
Chronic Obstructive Pulmonary Disease (COPD)
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will assess the efficacy and safety of QVA149 compared to tiotropium plus formoterol in patients with moderate to severe COPD.
- Trial name
- QUANTIFY (NCT01574651)
- Testing
- QVA149, Tiotropium, Formoterol
- Where
- 144 sites in Germany
- Volunteers
- 934 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Tiotropium / Respimat One Year Study in COPD.
The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD.
- Trial name
- NCT00387088
- Testing
- Respimat, Tiotropium
- Where
- 334 sites in United States, Australia and 29 more
- Volunteers
- 3,991 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Residential Cleaning of Indoor Air to Protect COPD Patients
This study looks at whether air cleaning devices put in the bedroom and living room of your home could reduce the irritation of your lungs and body that is caused by indoor air pollution.
- Trial name
- CARE (NCT03750292)
- Testing
- HEPAirX air filter, control air filter
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Rochester